CVS Health Corporation operates an integrated health care model that combines retail pharmacy, pharmacy benefit management, health insurance, medical clinics, specialty and mail pharmacy support, and related consumer health services. Recurring company news includes quarterly results and guidance, segment performance across Health Services, Health Care Benefits, and Pharmacy & Consumer Wellness, and capital returns through common-stock dividends.
Updates also cover CVS Caremark formulary decisions, biosimilar adoption, Aetna prior authorization and plan-administration initiatives, community health investments by the CVS Health Foundation, and developments involving Omnicare, the company's long-term care pharmacy subsidiary.
ARCTRUST Private Capital acquired a seven-property, single-tenant net lease portfolio for its planned ARCTRUST Exchange II DST, targeting 1031 exchange investors.
The portfolio totals about 51,192 square feet on 7.75 acres, spans six states, has a 13.6-year weighted average lease term, and features absolute triple-net leases with CVS Pharmacy (NYSE: CVS), Pinnacle Bank, and NAPA Auto Parts–branded locations.
Salesforce (NYSE: CRM) and CVS Health are expanding their decade-long collaboration to enhance call center care using Agentforce Health, Salesforce's AI-powered health solution.
The platform will support Aetna and CVS Caremark, serving millions of members and 1.5 million providers with faster, more personalized, data-driven interactions.
CVS Health (NYSE: CVS) is expanding GLP-1 weight management coverage through CVS Caremark’s commercial formularies. Zepbound (tirzepatide) will be reintroduced as an additional preferred option on October 1, 2026, and the new-to-market block on oral GLP-1 Foundayo (orforglipron) ends June 1, 2026, where plans approve coverage.
According to CVS Health, these formulary updates aim to improve affordability and access for plan sponsors and members via manufacturer negotiations, while maintaining plan flexibility and providing education and clinical support for smooth transitions.
Aetna, a CVS Health company (NYSE: CVS), launched the second‑generation Claims Assist Manager (CAM), an AI‑powered claims advisor platform that streamlines complex claims processing and improves payment accuracy.
CAM’s adjuster AI agents cut processing time by over 20% for manually reviewed claims and support CVS Health’s $20 billion multi‑year digital innovation investment to reduce administrative burden and enhance provider and member experience.
Glenview Capital reported on its investment in CVS Health (NYSE: CVS), noting an 80% total return on shares purchased since May 2024. After healthy Q1 results and higher annual guidance, Glenview rebalanced in May 2026, selling 3.75 million shares while keeping CVS among its three largest positions and reaffirming strong confidence in CVS’s near-, medium-, and long-term outlook.
CVS Health (NYSE:CVS) joined partners to open The Mews at St. Mary, a 75-unit senior affordable housing community in Williamstown, New Jersey.
The project is funded by a $9 million CVS investment plus HUD and NJHMFA support, and offers on-site medical, wellness, and social services for older adults.
CVS Health reports over $40 million invested in New Jersey affordable housing to date and an estimated $12.5 billion economic impact in the state in fiscal 2024.
CVS Health (NYSE: CVS) highlighted its ongoing support for service members, veterans, and military families across care, community, purpose, and economic opportunity.
Programs span TRICARE and MinuteClinic access, community partnerships, well-being initiatives, and entrepreneurship support, including $292 million in 2025 spending with veteran-owned small businesses.
CVS Health (NYSE: CVS) released a white paper, “Navigating the Digital Health Literacy Gap,” highlighting challenges Medicare-eligible older Americans face with digital health tools.
Key findings: 58% say low digital literacy harms health management, 85% struggle with platform navigation, yet 86% are open to using digital tools and 71% want more engagement.
CVS Health is responding through a $20 billion technology investment, with initiatives like intuitive pharmacy self-service, personalized digital Care Paths, and Oak Street Health community classes to improve usability, access, and support for this growing, clinically complex population.
CVS Health (NYSE: CVS) and WGU launched an online Associate of Science–Health Science, Pre-Pharmacy program for CVS colleagues, including pharmacy technicians. The two-year, 26-course program offers flexible, mentor-supported study and is designed to meet PharmD prerequisites while reducing education costs through tuition discounts and reimbursement.
With an exclusive WGU tuition rate of $3,989 per six‑month term and up to $3,000 per year in CVS Health tuition reimbursement, participants can complete the program with an estimated out‑of‑pocket cost of $9,956. Courses are expected to begin in summer 2026.
Omnicare, a CVS Health (NYSE: CVS) subsidiary, received U.S. Bankruptcy Court approval to sell its business to GenieRx Holdings, a partnership of Milrose Capital and Integro Healthcare Services. The transaction is expected to close later in 2026, pending regulatory approval and customary closing conditions.
Omnicare plans to continue delivering pharmacy services, emphasizing transparent pricing, clinically aligned programs, and a compliance-first approach throughout the court-supervised process.